trial

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

NCTId NCT05389787
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 40 (estimated)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2027-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Double
Start
2022-08-18
Primary completion
2027-08-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Transcranial Magnetic Stimulation

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2027-08-31
Status
RECRUITING
relationships
The graph out of here
drug
Transcranial Magnetic Stimulation
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
indication
Schizophrenia
indication
Condition
indication
Schizophrenia
indication